Abstract
Background: Silimarin is the dry mixture of a whole family of natural substances, extracted after the addition of ethanol, methanol, and acetone. Silimarin consists mainly of silibin A and silibin B, as well as other less important compounds.
Methods: Silimarin has been demonstrated to “inhibit cell proliferation and to induce apoptosis, while also having anti-angiogenic properties.” The induction of apoptosis in cancer cells has been mediated by the involvement of ER stress.
Results: Silibinin has the potential to operate as a STAT3-targeted inhibitor as well as an inhibitor of the upregulation of the immune checkpoint regulator PD-L1 and also EMT regulators, thus being a promising adjuvant in NSCLC. It has also been documented to suppress cancer cells be means of down- regulating actin cytoskeleton and PI3K / Akt molecular pathways. Several studies have demonstrated that silibinin exerts its protective potential partly through interacting with the tumor suppressor gene p53.
Conclusions: It is noteworthy that research has been carried out on the enhancement of silimarin’s bioavailability, especially by the preparation of specific nanoformulas, and its probable additional use together with the chemotherapeutic regimens in the near future.
Keywords: Silimarin, silibin, apoptosis, anti-angiogenic properties, bioavailability, PD-L1, EMT regulators, inhibit cell proliferation.
Anti-Cancer Agents in Medicinal Chemistry
Title:Silimarin and Cancer
Volume: 18 Issue: 14
Author(s): Christina Liakopoulou, Christos Kazazis and Natalia G. Vallianou*
Affiliation:
- Evangelismos General Hospital, 45-47 Ipsilantou Str, 10676, Athens,Greece
Keywords: Silimarin, silibin, apoptosis, anti-angiogenic properties, bioavailability, PD-L1, EMT regulators, inhibit cell proliferation.
Abstract: Background: Silimarin is the dry mixture of a whole family of natural substances, extracted after the addition of ethanol, methanol, and acetone. Silimarin consists mainly of silibin A and silibin B, as well as other less important compounds.
Methods: Silimarin has been demonstrated to “inhibit cell proliferation and to induce apoptosis, while also having anti-angiogenic properties.” The induction of apoptosis in cancer cells has been mediated by the involvement of ER stress.
Results: Silibinin has the potential to operate as a STAT3-targeted inhibitor as well as an inhibitor of the upregulation of the immune checkpoint regulator PD-L1 and also EMT regulators, thus being a promising adjuvant in NSCLC. It has also been documented to suppress cancer cells be means of down- regulating actin cytoskeleton and PI3K / Akt molecular pathways. Several studies have demonstrated that silibinin exerts its protective potential partly through interacting with the tumor suppressor gene p53.
Conclusions: It is noteworthy that research has been carried out on the enhancement of silimarin’s bioavailability, especially by the preparation of specific nanoformulas, and its probable additional use together with the chemotherapeutic regimens in the near future.
Export Options
About this article
Cite this article as:
Liakopoulou Christina, Kazazis Christos and Vallianou G. Natalia*, Silimarin and Cancer, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (14) . https://dx.doi.org/10.2174/1871520618666180905154949
DOI https://dx.doi.org/10.2174/1871520618666180905154949 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Health Benefits of Manuka Honey as an Essential Constituent for Tissue Regeneration
Current Drug Metabolism Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry Non-invasive Biodiversified Sensors: A Modernized Screening Technology for Cancer
Current Pharmaceutical Design Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine The Use of Mathematical Modelling for Improving the Tissue Engineering of Organs and Stem Cell Therapy
Current Stem Cell Research & Therapy Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Targeting Calcium Channels to Block Tumor Vascularization
Recent Patents on Anti-Cancer Drug Discovery Identification of Biomarkers and Functional Modules from Genomic Data in Stage-wise Breast Cancer
Current Bioinformatics Applications of X-Ray Diffraction Imaging to Mammography
Recent Patents on Medical Imaging Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review
Recent Patents on Anti-Cancer Drug Discovery P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry Peroxisome Proliferator-activated Receptor-γ As A Novel and Promising Target For Treating Cancer <i>Via</i> Regulation of Inflammation: A Brief Review
Mini-Reviews in Medicinal Chemistry TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Cancer Estimates in Brazil Reveal Progress for the Most Lethal Malignancies
Current Topics in Medicinal Chemistry Application of 3D Biomimetic Models in Drug Delivery and Regenerative Medicine
Current Pharmaceutical Design Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy